MKI67 and gastrointestinal stromal tumor: In the following, GIST PCTSs from three patients were treated with 2 μM imatinib, and the response to TKI treatment was analysed via multiplex immunofluorescence (mIF) and Ki-67 staining and ATP-based viability assays (Figure 3).